Natco Pharma shines on getting nod from CDSCO for emergency use of Baricitinib tablets

Apurva Joshi
/ Categories: Trending, Mindshare, DSIJ News
Natco Pharma shines on getting nod from CDSCO for emergency use of Baricitinib tablets

Natco Pharma Limited has informed the bourses that it has received emergency use approval for Baricitinib tablets in strengths of 1 mg, 2 mg, and 4 mg from Central Drugs Standard Control Organisation (CDSCO), India. Baricitinib, combined with Remdesivir, is used for the treatment of COVID-19 positive patients. 

Natco will be requesting a compulsory licence, based on emergency use and in light of the grave & serious public health emergency across India due to the pandemic. The company is ready to launch the product this week, so as to make the product available to all the patients across the country. 

In April, the company had applied to CDSCO, India for the approval of phase-III clinical trial of Molnupiravir capsules for the treatment of COVID-19 positive patients. It is hoping that CDSCO would give emergency approval of this drug based on ‘compassionate use’ for patients. 

Natco Pharma mainly operates through three key segments i.e. oncology, speciality pharma, cardiology & diabetology. Currently, in the US market, the company has 23 active commercial products while 5 ANDAs are in the pipeline. 

With this, the stock of Natco Pharma was trading 4.3 per cent higher at Rs 935 from its previous close of Rs 896.65 on BSE. 

Rate this article:
5.0

1 comments on article "Natco Pharma shines on getting nod from CDSCO for emergency use of Baricitinib tablets"

Avatar image

Madan Keshari

With its presence in the critical areas such as oncology, speciality pharma, cardiology and diabetology. Narco Pharma is to emerge into a major pharma entry on the global scene. The stock has just begun its upward journey.

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary28-Mar, 2024

Multibaggers28-Mar, 2024

Interviews28-Mar, 2024

Multibaggers28-Mar, 2024

Multibaggers28-Mar, 2024

Knowledge

General26-Mar, 2024

MF25-Mar, 2024

General18-Mar, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR